MarketBeat
22 Nov 2026, 03:12 UTC · 1h ago
Lakefront Biotherapeutics Eyes 2027 Trials for Autoimmune Drug, Backed by €2.2 Billion in Cash
Impact · against what's priced in
Lakefront Biotherapeutics (LKFT) shows significant positive momentum through a combination of aggressive cost-cutting, a massive cash cushion, and new pipeline expansions. Gilead (GILD) gains slight upside as the market does not currently price in the potential revenue from these specific near-term pipeline partnerships.
- GILD+0.20
Challenges what's priced in
- The price assumes





